The researchers from Scripps Research and the University of North Carolina (UNC), US, found this includes not only the Covid-19-causing SARS-CoV-2, but also SARS-CoV-1 and MERS-CoV.
The study, published in the journal Immunity, could lead to the development of a broad coronavirus vaccine and related antibody therapeutics. Both could be used against future coronavirus pandemics as well as any future variants of SARS-CoV-2.
“We show here that there are individual human monoclonal antibodies that can be found that protect against all three recent deadly coronaviruses: SARS-CoV-1, SARS-CoV-2 and MERS-CoV,” said study co-senior author Raiees Andrabi, institute investigator at Scripps Research.
SARS-CoV-2, along with SARS-CoV-1 — the cause of the 2002-04 SARS outbreak — and MERS-CoV, the cause of deadly Middle East Respiratory Syndrome, belong to a broad grouping of coronaviruses known as betacoronaviruses.
These viruses mutate at a modestly high rate, creating a significant challenge for the development of vaccines and antibody therapies against them.
In the case of SARS-CoV-2, although existing vaccines have been very helpful in limiting the toll of disease and death from the pandemic, new SARS-CoV-2 variants have emerged that can spread even among vaccine recipients.
However, over the past two years, the team has been finding evidence that SARS-CoV-2 and other betacoronaviruses have a vulnerable site that does not mutate much. This site, which is in the S2 region (or base) of the viral spike protein, is relatively conserved on betacoronaviruses that infect a variety of animal species.
By contrast, current SARS-CoV-2 vaccines mainly target the viral spike protein’s relatively mutable S1 region, with which the virus binds to host-cell receptors.
The S2 site plays a key role in how betacoronaviruses progress from receptor-binding to the membrane fusion that enables entry into host cells in the respiratory tract.
In a study published last year, the team found that some human antibodies can bind to this site on SARS-CoV-2 in a way that apparently disrupts viral fusion and blocks infection.
The existence of such a vulnerable site raises the possibility of targeting it to provide both long-lasting and broad protection against betacoronaviruses.
In the latest study, the researchers made a more comprehensive search for anti-S2 antibodies in blood samples from human volunteers.
These volunteers were individuals who had recovered from Covid-19, had been vaccinated, or had recovered from Covid-19 and then had been vaccinated.
The researchers found that antibodies to the vulnerable S2 site were present in the vast majority of volunteers in the latter group — people who had recovered from Covid-19 and then had been vaccinated — but at a much lower frequency in the others.
Overall, the researchers identified and characterised 32 of these S2-targeting antibodies.
In lab virus neutralisation studies and in virus-challenge studies with mice, the researchers found that several of these antibodies provide protection of unprecedented breadth — not only against SARS-CoV-2 but also SARS-CoV-1 and MERS-CoV betacoronaviruses.
“In principle, a vaccination strategy that can induce such antibodies is likely to provide broad protection against a diverse spectrum of betacoronaviruses,” said Burton.
Structural studies of several of the antibodies when bound to S2 illuminated their common binding sites and modes of binding, providing key information that should aid the development of future vaccines targeting this region.
“Targeted rational vaccine strategies could take advantage of this molecular information of the interactions of these antibodies with the S2 domain to inform the design of pan-betacoronavirus vaccines,” Wilson said.